Generating and Characterizing Subtype Specific Versions of Oligodendrogenic Neural Progenitor Cells for the Treatment of Spinal Cord Injury
Spinal cord injury (SCI) leads to devastating sensory and motor impairments which severely diminish quality of life and currently have no cure. Although different cell therapies have been tested for SCI, many have been transplanted in a “one size fits all” approach and have insufficiently addressed patients’ diverse injuries. As such, many pre-clinical efforts have failed to be translated to a clinical setting. In the present study, we aim to generate and characterize three distinct versions of cells in order to promote patient-specific treatment of SCI. We expect that this approach will help clinicians allocate patients to distinct treatment paradigms in order to optimally facilitate therapeutic recovery.